Maternal Use of Anti-asthmatic Drugs and Infant Congenital Malformations
Most likely there is an association between maternal use of anti-asthmatic drugs and infant congenital malformations. It is not strong and appears rather unspecific as it can be seen after different types of anti-asthmatic drugs and on some different malformation types. It is likely that these effects to a large extent are due to confounding by indication so that they are caused by underlying asthma disease. It is important that women with asthma get necessary therapy during pregnancy and there seems to be little difference in the teratogenic effect of at least most used drugs. For some drug types, available information is limited, e.g., for xanthine derivatives and leukotriene antagonists, and further data are needed. The available information does not indicate any marked risks with these drugs, still less is known about the use of the monoclonal anti-IgE antibody omalizumab.
- Garne E, Hansen AV, Morris J, Zaupper L, Addor M-C, Barisic I, Gatt M, Lelong N, Klungsøyr K, O’Mahony M, Nelen V, Neville AJ, Pierini A, Tucker D, de Walle H, Wiesel A, Loane M, Dolk H. Use of asthma medication during pregnancy and risk of specific malformations: a European case-malformed control study. J Allergy Clin Immunol. 2015;136:1496–502.CrossRefGoogle Scholar
- Källén B. Maternal asthma and use of antiasthmatic drugs in early pregnancy and congenital malformations in the offspring. J Pulm Respir Med. 2004;4:166. https://doi.org/10.4172/2161-105X.1000/66.
- Merck. Pregnancy registry to Singulair®: the 8th annual report 2006. West Point: Merck Research Laboratories; 2007.Google Scholar
- Nelsen LM, Shields KE, Cunningham ML, Stoles JM, Bamshad MJ, Eng PM, Smugar SS, Gould AL, Philip G. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. Letter to the editor. J Allergy Clin Immunol. 2012;129:251.CrossRefGoogle Scholar